How Many People Take Zepbound? An In-Depth Look at Its Impact

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound (semaglutide) and tirzepatide-based therapies have become some of the most prescribed medications for weight management in the United States. Since tirzepatide's FDA approval in late 2023, millions of patients have begun treatment, with demand continuing to reshape the weight loss medication landscape. Understanding adoption trends helps patients make informed decisions about their own therapy options.

Understanding GLP-1 Receptor Agonist Adoption Rates

Prescription data shows that tirzepatide and semaglutide have reached critical adoption milestones across American healthcare. By mid-2024, pharmacy networks reported filling hundreds of thousands of GLP-1 prescriptions monthly, with tirzepatide gaining market share due to its dual-receptor mechanism targeting both GLP-1 and GIP pathways. This surge reflects not only increased clinical confidence but also growing patient awareness of these medications' effectiveness for sustainable weight loss.

The rapid uptake has created access challenges, including supply constraints and insurance authorization delays. Many patients turn to compounded versions from licensed 503A pharmacies as an alternative to brand-name medications. PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) and requires no insurance, making it accessible across all 50 states without membership fees or hidden costs.

Why Tirzepatide Therapy Is Becoming the Preferred Choice

Tirzepatide's dual action on GLP-1 and GIPR receptors produces weight loss outcomes that often exceed single-receptor agonists. Clinical trials demonstrated average weight reductions of 20–22% over 68 weeks in patients with obesity, compared to 14–17% with semaglutide alone. This superior efficacy has driven patient demand and influenced prescribing patterns among weight loss specialists and primary care physicians.

Beyond raw weight reduction, tirzepatide users report improvements in metabolic markers, including reduced fasting blood glucose and improved insulin sensitivity. These outcomes have made tirzepatide particularly attractive for patients with concurrent type 2 diabetes or prediabetes. PlexusDx offers both compounded tirzepatide injection and oral formulations, allowing patients to select the delivery method that best fits their lifestyle and preferences.

Demographics and Patient Populations Using GLP-1 Therapy

GLP-1 adoption spans diverse demographic groups, though uptake has been highest among patients aged 40–65 with household incomes above $50,000. Both men and women seek these therapies, though women represent a slightly larger portion of the patient population. Healthcare systems have also expanded access to underrepresented communities, though insurance barriers and awareness gaps remain challenges.

PlexusDx serves patients nationwide regardless of demographic background, income level, or prior insurance status. HSA and FSA accounts are accepted, removing additional financial obstacles. The Precision Peptide Genetic Test ($298) helps identify individual genetic predispositions across 14 pathways and 49 peptides, enabling personalized dosing strategies that may improve outcomes across all patient populations.

Comparing Compounded and Brand-Name GLP-1 Options

Brand-name Zepbound and Mounjaro command premium prices and depend heavily on insurance coverage or cash-pay arrangements. Compounded tirzepatide from licensed 503A pharmacies offers chemically equivalent active ingredients at lower cost without requiring prior authorization. PlexusDx compounded tirzepatide injection ($289/month flat) and oral tirzepatide ($349/month) provide price certainty—your dose may need to go up, but your price won't.

Both compounded and brand-name formulations contain the same active pharmaceutical ingredients, though sourcing, formulation methods, and delivery systems vary. PlexusDx partners exclusively with licensed 503A compounding pharmacies, never 503B facilities, ensuring pharmaceutical-grade quality and sterile compounding practices. Patients choosing compounded tirzepatide receive the same clinical benefits alongside greater affordability and accessibility.

The Role of Genetic Testing in Personalizing GLP-1 Therapy

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Patients completing the genetic test gain insights into their peptide pathways and can work with PlexusDx clinicians to optimize their treatment plan from the start. Rather than following standard dose escalation schedules, personalized dosing based on genetic data may accelerate reaching an effective maintenance dose while minimizing side effects. The test costs just $298.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How many people currently use Zepbound or tirzepatide in the U.S.?

An estimated 3–4 million Americans have received prescriptions for tirzepatide or semaglutide-based therapies as of late 2024, with monthly prescription volumes continuing to rise. Exact numbers fluctuate due to supply availability and insurance authorization timelines. PlexusDx has helped thousands of patients access compounded tirzepatide across all 50 states without insurance requirements.

What percentage of weight loss can I expect with tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is PlexusDx compounded tirzepatide covered by insurance?

PlexusDx compounded tirzepatide requires no insurance and is not insurance-dependent, making it accessible nationwide. Tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) flat, and oral tirzepatide is $349/mo month-to-month (or $279/mo on the 6-month plan). HSA and FSA accounts are eligible, and all 50 states are served without membership fees.

What are the common side effects of tirzepatide therapy?

No — the Precision Peptide Genetic Test does not predict your response to Zepbound or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How does the PlexusDx Precision Peptide Genetic Test help with tirzepatide therapy?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Fridays Zepbound

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.